A Phase 4 interventional study of Trifarotene cream and Doxycycline hyclate in Acne Vulgaris, sponsored by Galderma R&D. Completed at 26 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2022-05-10.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing trifarotene in Acne Vulgaris — none open to participants now, 1 under way, 1 of them phase 3. trifarotene · Acne Vulgaris.
Among the 12 studies testing trifarotene in Acne Vulgaris, this one is the 9th largest by enrollment, is the only one that started in 2020, is one of 3 in phase 4, and was the 6th registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →None of the 12 studies testing trifarotene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →
trifarotene: first FDA approval 2019 (AKLIEF). What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2020.
This study's enrollment of 202 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 507 across the 12 interventional studies. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 3 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
49 studies in Acne Vulgaris by Galderma Group AG: none open now, 1 under way, 1 of them phase 3. Of 48 finished, 39 (81%) have results posted.
Among the 49 studies in Acne Vulgaris by Galderma Group AG, this one is the 23rd largest by enrollment of the 46 interventional ones that give a count, is the only one that started in 2020, is one of 20 in phase 4, and was the 46th registered.
Galderma Group AG’s Acne Vulgaris studies by the year they started, since 2004.
1 of the studies testing trifarotene in Acne Vulgaris that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186413Phase 3Galderma R&DA Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing trifarotene in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 49 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to demonstrate that daily use of topical trifarotene (CD5789) 50 microgram per gram (mcg/g) cream when used in association with oral antibiotic is safe and effective for the treatment of severe AV.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were applied with Trifarotene (CD5789) 50 micrograms per gram (mcg/g) cream topically on the face once daily in the evening for 12 weeks and received doxycycline 120 milligrams (mg) tablet orally once daily in the evening and 1 tablet in the morning on Day 2 of every week for 12 weeks.
Drug: Trifarotene cream · Drug: Doxycycline hyclate
Participants were applied with vehicle CD5789 topically on the face once daily in the evening for 12 weeks and received doxycycline matching placebo tablet orally once daily in the evening and 1 tablet in the morning on Day 2 of every week for 12 weeks.
Drug: Trifarotene Vehicle · Drug: Doxycycline Placebo
Trifarotene 50 mcg/g cream applied topically once daily on face for 12 weeks.
Also known as: AKLIEF
Doxycycline hyclate delayed release 120 mg tablets was administered orally for 12 weeks.
Also known as: DORYX MPC
Trifarotene 50 mcg/g vehicle cream was applied topically once daily on face for 12 weeks.
Doxycycline hyclate delayed release 120 mg placebo tablets was administered orally for 12 weeks.
Absolute Change From Baseline in Facial Total Lesion Counts to Week 12
Total lesion counts corresponded to the sum of inflammatory and non-inflammatory lesions, and papules. The investigator (or subinvestigator) counted all inflammatory lesions (papules, pustules, and nodular lesions) and non-inflammatory lesions (open and closed comedos; diagnosis based on palpation) on the face.
Time frame: From Baseline to Week 12
Absolute Change From Baseline in Facial Inflammatory Lesions (IL) Counts to Week 12
All inflammatory lesions (papules, pustules, and nodular lesions) were counted by investigator/subinvestigator.
Time frame: From Baseline to Week 12
Absolute Change From Baseline in Facial Non Inflammatory Lesions (NIL) Counts to Week 12
Non-inflammatory lesions (open and closed comedo) were counted by investigator/subinvestigator.
Time frame: From Baseline to Week 12
Percentage of Participants Who Achieved an IGA Score of 1 (Almost Clear) or 0 (Clear) and At Least a 2-Grade Improvement From Baseline to Week 12
IGA was an assessment scale used to evaluate facial acne severity. IGA was recorded from components collected on the case report form (CRF) using a 5-point scale where (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on inflammation, pustules and papulation/infiltration. Success Rate was defined as the percentage of participants who achieved an IGA score of 1 (Almost Clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12.
Time frame: From Baseline to Week 12
Study was conducted at United States of America and Puerto Rico between 29 Jul 2020 and 26 Apr 2021.
| Milestone | Trifarotene (CD5789) Cream + Doxycycline | Trifarotene Vehicle + Doxycycline Placebo |
|---|---|---|
| Started | 133 | 69 |
| Completed | 123 | 65 |
| Not completed | 10 | 4 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Lost to follow-up | 5 | 0 |
| Withdrew: Withdrawal by subject | 3 | 1 |
| Withdrew: Withdrawal by parent/guardian | 1 | 0 |
| Withdrew: Other than specified | 0 | 1 |
Total lesion counts corresponded to the sum of inflammatory and non-inflammatory lesions, and papules. The investigator (or subinvestigator) counted all inflammatory lesions (papules, pustules, and nodular lesions) and non-inflammatory lesions (open and closed comedos; diagnosis based on palpation) on the face.
| Lesion counts | Trifarotene + Doxycycline | Trifarotene Vehicle + Doxycycline Placebo |
|---|---|---|
| Absolute Change From Baseline in Facial Total Lesion Counts to Week 12 | -69.1 ± 2.28 | -48.1 ± 3.14 |
All inflammatory lesions (papules, pustules, and nodular lesions) were counted by investigator/subinvestigator.
| Lesion counts | Trifarotene + Doxycycline | Trifarotene Vehicle + Doxycycline Placebo |
|---|---|---|
| Absolute Change From Baseline in Facial Inflammatory Lesions (IL) Counts to Week 12 | -29.4 ± 1.09 | -19.5 ± 1.49 |
Non-inflammatory lesions (open and closed comedo) were counted by investigator/subinvestigator.
| Lesion counts | Trifarotene + Doxycycline | Trifarotene Vehicle + Doxycycline Placebo |
|---|---|---|
| Absolute Change From Baseline in Facial Non Inflammatory Lesions (NIL) Counts to Week 12 | -39.5 ± 1.42 | -28.2 ± 1.96 |
IGA was an assessment scale used to evaluate facial acne severity. IGA was recorded from components collected on the case report form (CRF) using a 5-point scale where (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on inflammation, pustules and papulation/infiltration. Success Rate was defined as the percentage of participants who achieved an IGA score of 1 (Almost Clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12.
| percentage of participants | Trifarotene + Doxycycline | Trifarotene Vehicle + Doxycycline Placebo |
|---|---|---|
| Percentage of Participants Who Achieved an IGA Score of 1 (Almost Clear) or 0 (Clear) and At Least a 2-Grade Improvement From Baseline to Week 12 | 31.7 | 15.8 |
Collected over From Baseline up to Week 12.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trifarotene + Doxycycline | 0/133 (0%) | 1/133 (0.8%) | 0/133 (0%) |
| Trifarotene Vehicle + Doxycycline Placebo | 0/69 (0%) | 0/69 (0%) | 0/69 (0%) |
| Event | Trifarotene + Doxycycline | Trifarotene Vehicle + Doxycycline Placebo |
|---|---|---|
| Self-Injurious IdeationPsychiatric disorders | 1/133 | 0/69 |
Analysis was performed on Intent to treat (ITT) population that included all participants who were randomized.
| Age, Continuous(years) | Trifarotene + Doxycycline | Trifarotene Vehicle + Doxycycline Placebo | Total |
|---|---|---|---|
| Mean | 20.0 ± 7.30 | 20.3 ± 8.92 | 20.1 ± 7.87 |
| Sex: Female, Male(Participants) | Trifarotene + Doxycycline | Trifarotene Vehicle + Doxycycline Placebo | Total |
|---|---|---|---|
| Female | 80 | 43 | 123 |
| Male | 53 | 26 | 79 |
| Ethnicity (NIH/OMB)(Participants) | Trifarotene + Doxycycline | Trifarotene Vehicle + Doxycycline Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 50 | 20 | 70 |
| Not Hispanic or Latino | 83 | 49 | 132 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Trifarotene + Doxycycline | Trifarotene Vehicle + Doxycycline Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 6 | 3 | 9 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 9 | 6 | 15 |
| White | 114 | 58 | 172 |
| More than one race | 3 | 2 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Facial Total Lesions Counts(Lesion counts) | Trifarotene + Doxycycline | Trifarotene Vehicle + Doxycycline Placebo | Total |
|---|---|---|---|
| Mean | 101.5 ± 40.11 | 100.7 ± 33.91 | 101.2 ± 38.02 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2020 to primary completion in Apr 2021, 8 months.
Results were first posted in May 2022, 1 year after primary completion.
Of 45 phase 4 interventional studies under Acne Vulgaris, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 8 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trifarotene